Hoth Therapeutics secures Japanese patent for mast cell disease treatment

Published 12/06/2025, 14:26
Hoth Therapeutics secures Japanese patent for mast cell disease treatment

NEW YORK - Hoth Therapeutics, Inc. (NASDAQ:HOTH), whose stock has surged over 55% in the past six months according to InvestingPro data, has obtained a patent in Japan for its HT-KIT platform technology targeting mast cell diseases, the clinical-stage biopharmaceutical company announced Thursday.

The Japan Patent Office granted Patent No. 7677628 on May 7, providing exclusive protection until August 27, 2039. The patent, titled "Targeting KIT with Splice Switching Oligonucleotides to Induce Apoptosis of Mast Cells," covers the company’s approach of using splice-switching oligonucleotides to disrupt KIT gene expression in mast cells.

Mast cells are implicated in various conditions ranging from chronic hives to rare cancers. The technology could potentially address both inflammatory and oncologic conditions driven by mast cells.

"Securing intellectual property protection in Japan—a globally significant pharmaceutical market—underscores the global value of HT-KIT," said Robb Knie, CEO of Hoth Therapeutics, in the press release statement.

The company indicated it is seeking strategic global partners, particularly in Asia, for co-development and commercialization opportunities. The HT-KIT platform is one of several novel technologies under development at Hoth.

The patent protection extends for approximately 14 years, potentially allowing the company to maintain market exclusivity for its technology in Japan through 2039 if commercialized.

Hoth Therapeutics focuses on developing treatments for various conditions, with an emphasis on early-stage pharmaceutical research and development.

In other recent news, Hoth Therapeutics has announced an Expanded Access Program (EAP) for its investigational drug HT-001, aimed at treating skin toxicities from epidermal growth factor receptor (EGFR) inhibitor therapies. This initiative allows patients who do not qualify for clinical trials to potentially access the treatment, as the company continues its Phase 2a clinical trial. Additionally, Hoth Therapeutics has made significant progress with HT-001, with plans to present interim clinical trial results at a Key Opinion Leader event. The company has also received a USPTO Filing Receipt for a new patent application for HT-001, strengthening its intellectual property strategy.

In other developments, Hoth Therapeutics reported promising preclinical results for HT-KIT, an antisense oligonucleotide therapy targeting rare cancers. The studies showed substantial tumor growth inhibition and a favorable safety profile, with plans to submit an Investigational New Drug (IND) application to the FDA in early 2026. Furthermore, Hoth Therapeutics confirmed the payment of fees for an international patent application related to hair loss treatment through its subsidiary, Merveille.ai. The company also secured a patent from the Japan Patent Office for its RNA-based cancer therapy targeting the KIT gene, enhancing its position in the RNA therapeutics field. These recent developments highlight Hoth Therapeutics’ ongoing efforts in advancing their pipeline and securing intellectual property rights.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.